Background {#Sec1}
==========

Smoking and tuberculosis (TB) are two of the biggest public health problems worldwide \[[@CR1]\]. Smoking is one of the leading preventable causes of premature death, producing 6 million deaths a year. At present, about 33 % of the world population smokes, mainly in countries with a high prevalence of TB. In turn, TB causes 9.6 million incident cases and 1.5 million deaths in 2014 \[[@CR2], [@CR3]\].

While, the relationship between smoking and TB has been recognized for almost a century, the impact of smoking on TB has only been demonstrated in last decade \[[@CR4]--[@CR7]\]: both active and passive exposure to smoke are independent risk factors for TB infection \[[@CR8], [@CR9]\], the progression of TB infection to disease \[[@CR10], [@CR11]\], greater disease severity, and increased risk of post-treatment relapse and mortality \[[@CR12]--[@CR14]\].

A recent study based on mathematical modelling estimated that, between 2010 and 2050, smoking could raise the number of TB cases worldwide by 18 million, and substantially increase secondary mortality if current trends in tobacco consumption are maintained \[[@CR15]\]. The World Health Organization and the International Union Against Tuberculosis and Lung Disease issued regulations in 2007 to control these two clearly related epidemics \[[@CR1]\].

Smoking prevalence among TB patients could be higher than the objectified general population in many countries; in China a case-control study shows prevalence of 54.6 % \[[@CR16]\], in South Africa found that 56 % of people with active TB were smokers \[[@CR17]\], a study in rural India found that 81.5 % of TB cases had previously smoked at some time in their life \[[@CR18]\] and in Georgia the prevalence of current smokers among the diagnoses of TB represents 45.9 % \[[@CR19]\]. Currently, there are no reliable data on the prevalence of smoking among TB patients in Spain, with the exception of one study carried out in Catalonia between 1996 and 2002, which reported a smoking prevalence of 34.9 % \[[@CR12]\].

The aim of our study was to determine the prevalence of smoking among patients diagnosed with TB in Spain between 2006 and 2013, and to identify factors associated with smoking in this population. The ultimate goal is to design assistance and support strategies for smoking cessation to improve clinical outcomes, reduce TB transmissibility, and improve prognosis and survival.

Methods {#Sec2}
=======

We performed a multicenter, cross-sectional, descriptive, analytical and observational study.

We included patients diagnosed with TB between 1 January 2006 and 31 December 2013 within the catchment area of the Integrated TB Research Program (PII TB) Working Group of the Spanish Society of Pneumology and Thoracic Surgery (SEPAR) in 60 centers in Spanish Autonomous Communities.

We included patients aged \>18 years with a diagnosis of TB, as determined by: 1) positive smear, or negative smear with positive culture for *Mycobacterium tuberculosis*, or extra-pulmonary TB as demonstrated by granulomas tubercular on histology; 2) patients suspected TB (clinical, radiological, epidemiological and/or laboratory results) with a good response to TB treatment without other diagnosis.

Patients were considered to be smokers if they reported having smoked ≥1 cigarettes per day continuously during the year preceding the diagnosis of TB and no smoker the person who has smoked less than 100 cigarettes in his life \[[@CR20]\].

The information is collected by clinical researcher from the interview and review of the history in three visits: at the time of diagnosis, the second month and the end of treatment. For all cases, we collected socio-demographic data, living status, origin (native or immigrant), place of diagnosis, alcohol consumption (men consuming over 280 g alcohol per week, an women over 168 gr, were considered alcoholics), use of intravenous heroin or/and cocaine drugs (IDU), delayed diagnosis (\>50 days), TB localization, radiology, microbiology results and sensitivity study, history of TB, HIV infection, clinical progression, drug treatment, and treatment outcome (correct: cured, treatment completed; incorrect: therapeutic failure, moved away/transferred, lost to follow-up and death).

The information obtained from each patient was stored in an electronic data collection notebook (DCN) implemented in a software application available to each study investigator via a personal identifier and password.

The study was conducted according to the requirements of the Declaration of Helsinki and Spanish Data Protection Law 15/1999. All patients gave their informed consent to participate in this study, which was approved by the Clinical Research Ethics Committee of Vall d\'Hebron University Hospital Foundation - Research Institute.

Statistical analysis {#Sec3}
--------------------

We performed a descriptive study of the prevalence of smoking among participants, and the frequency distribution of other variables. We performed bivariate analysis of factors potentially associated with smoking (yes/no) by comparing proportions between groups using the *χ*^2^ test. Results with p \< 0.05 were considered statistically significant. For the multivariable analysis, we fit logistic regression models using the backward stepwise selection method to include variables that were relevant to the study, as well as those with p \< 0.001 in the bivariate analysis, and to compute Odds Ratios (OR) and 95 % Confidence Intervals (CI). We used the Hosmer-Lemeshow test to evaluate the goodness of fit of each model. All analysis was performed using IBM SPSS Statistic19.

Results {#Sec4}
=======

We included 5,846 TB patients; with a mean age of 39 years (range 18--100 years), 3,626 (62 %) men, and 1,941 foreigners (33 %). 23.4 % were pathological alcohol drinkers, and 1.3 % were IDU. 4.6 % of cases were coinfected with HIV, 438 (7.5 %) had a history of TB treatment, and 49.5 % were diagnosed by hospital emergency services. 6.6 % of cases were found to be resistant to any drug, and 0.8 % to multiple drugs. The predominant clinical presentation was pulmonary tuberculosis (4,149 cases, 71 %), with a cavitary radiological pattern in 32.8 % of cases. 82 % of cases were confirmed microbiologically, of which 54 % were smear-positive.

A total of 2,300 (39.3 %) patients were smokers, and this proportion remained stable during the course of the study Fig. [1](#Fig1){ref-type="fig"}.Fig. 1Trend in the prevalence of smoking in the general population and among smokers with tuberculosis 2006--2013

The bivariate analysis to detect factors associated with smoking (Table [1](#Tab1){ref-type="table"}) indicated a higher prevalence of smoking among men, Spanish nationals, and individuals who live alone or in confinement, or who are homeless, regardless of age or employment status. Smoking was also associated with other harmful habits, such as alcoholism and the use of injected drugs. Smoking was more frequent in cases with coexisting HIV infection, and those with a history of TB treatment. The prevalence of delayed diagnosis was significantly higher in smokers than in non-smokers. Pulmonary forms of TB, radiological cavitation, and positive smear-test results were more common in smokers, as was therapeutic non-compliance, and the need for directly observed treatment (DOT) administration and poorer treatment outcome. In contrast, we observed no differences between smokers and non-smokers in terms of single or multi-drug resistance, prescribed treatment, or clinical or radiological progression (Table [1](#Tab1){ref-type="table"}).Table 1Characteristics of 5,846 tuberculosis patients. Factors related to smoking at the time of tuberculosis diagnosis at bivariate levelTotalNon-smokerSmokerBivariate analysisN 5846N 354661 %N 230039 %OR (95 % CI)*P*-valueSex Women2082155674,752625,3Ref Men3626191152,7171547,32.65(2.36;2.99)\<0.001 Unknown1387957,25942,82.21(1.55;3.14)\<0,001Age Unknown13811885,52015,5Ref 18--30 years1627107766,255033,82.99(1.88;5.01)\<0,001 31--50 years2405121250,4119349,65.77(3.65;9.61)\<0,001  \> 50 years1676113968537322.76(1.74;4.62)\<0,001Origin Immigrant1941140872,553327,5Ref Native3905213854,8176745,22,18(1,94;2.46)\<0,001Cohabitation status Group65143166,222033,8Ref Alone55427649,827850,21,97(1,56;2,49)\<0,001 Homeless100252575755,84(3,65;9,63)\<0,001 Confinement803847,54252,52,16(1,35;3,47)0,001 With Family4293268362,5161037,51,18(0,99;1,40)0,067 Unknown1689355,47544,61,58(1,12;2,23)0,01Employment status Retired9787928118619Ref Active3026179459,3123240,72,92(2.46;3,95)\<0.001 Unemployed148173049,375150,74,38(3,63;5,30)\<0.001 Incapacity1105953,65146,43,68(2,44;5,53)\<0.001 Unknown25117168,18031,91,99(1,46;2,71)\<0.001Alcohol No4475307968,8139631,2Ref Yes137146734,190465,94,27(3.76;4,86)\<0,001IDU No5768353261,2223638,8Ref Yes781417,96482,17,15(4.12;13,4)\<0,001HIV No4547278361,2176438,81,10(0,96;1,27)0,15 Yes26910840,116159,92,60(1,97;3,92)0,001 Unknown103065563,537536.4RefDiagnosis Specialits service8986026729633Ref Hospital Emergency Room29161691581225421,47(1,26;1,73)\<0,001 Primere care110666059,744640,31,37(1,14;1,65)0,001 Other75449465,526034,51,07(0,87;1,31)0,515 Unknown1729957,67342,41,5(1,07;2,09)0,018Prior Treatment No5287324561,4204238,6Ref Yes43822451,121448,91,52(1,25;1,85)\<0,001Localization Extra-pulmonary61149781,311418,7Ref Pulmonary4149229955,4185044,63,50(2.84;4.35)\<0,001 Disseminated30119865,810334,22,27(1,66;3,10)\<0,001 Unknown78555270,323329,71,84(1,43;2,38)\<0,001Radiology Normal61048078,713021,3Ref Abnormal cavitary192288946,3103353,74,28(3.47;5,32)\<0,001 Abnormal non cavitary3114204265,6107233,41,94(1,58;2,39)\<0,001 Unknown20013567,56532,51,78(1,24;2,53)0,002Microbiology Culture (−)105577973,827626,2Ref Microscopy smear (+)31441636521508482,60(2,23;3,04)\<0,001 Microscopy smear (+), culture (−)1647113168,751631,31,29(1,08;1,53)0,004Single-drug resistance No5458331160,7214739,3Ref Yes38823560,615339,41,00(0,81;1,24)0,968Multi-drug resistance No5797351760,7228039,3Ref Yes492959,22040,81,07(0,59;1,88)0,827Delayed diagnosis Unknown34322665,911734,1Ref  \< 50 days2777168060,5109739,51,26(1,00;1,60)0,052  \> 50 days2726164060,2108639,81,28(1,01;1,62)0,04Treatment indicated Unknown197132676533Ref 3 drugs2566152159,3104540,71,39(1,03;1,91)0,032 4 drugs2819173261,4108738,61,27(0,94;1,74)0,119 Others26416161103391,30(0,88;1,92)0,186Need for DOT Unknown59737362,522437,5Ref No4629283461,2179538,81,05(0,89;1,26)0,555 Yes62033954,728145,31,38(1,10;1,74)0,006Clinical progression Unknown56935462,221537,8Ref Improved4860293660,4192439,61,08(0,90;1,19)0,406 Stable36822661,414238,61,03(0,79;1,35)0,805 Progressed493061,21938,81,05(0,56;1,89)0,884Radiological progression Stable98162663,835536,2Ref Improved3750223859,7151240,31,19(1,03;1,38)0,018 Progressed361747,21952,81,97(1,00;3,89)0,049 Unknown107966561,641438,41,10(0,92;1,31)0,307Treatment outcome Unknown52032462,319637,7Ref Correct5079312361,5195638,51,04(0,86;1,25)0,717 Incorrect2479940,114859,92,47(1,81;3,37)\<0,001*OR* odds ratio*CI* confidence interval*IDU* injecten drug users*HVI* humanimmunodeficiency virus

The multivariate analysis (Table [2](#Tab2){ref-type="table"}) showed that the following factors were associated with smoking at the time of diagnosis in this cohort of TB patients: male gender (OR = 2.26,CI 1.97--2.60), being native Spanish (OR = 2.79,CI 2.40--3.24), alcohol consumption (OR = 2.85,CI 2.46--3.31), IDU (OR = 2.78,CI 1.48--5.52), poverty (OR = 1.99,CI 1.14--3.57), pulmonary forms of TB (OR = 1.61,CI 1.16--2.24), cavitary radiological patterns (OR = 1.99,CI 1.43--2.79) and positive smear-test results (OR = 1.39, CI 1.14--1.71).Table 2Characteristics of 5,846 tuberculosis patients. Factors related to smoking at the time of tuberculosis diagnosis at multivariate levelTotalNon-smokerSmokerMulti-variate analysis.N 5846N 354661 %N 230039 %OR (95 % CI)*P*-valueSex Women2082155674,752625,3Ref Men3626191152,7171547,32.26(1.97;2.60)\<0.001 Unknown1387957,25942,82.19(1.46;3.28)\<0.001Age Unknown13811885,52015,5Ref 18--30 years1627107766,255033,82.39(1.44;4,13)\<0.001 31--50 years2405121250,4119349,63.45(2.09;5,94\<0.001  \> 50 years1676113968537322.52(1.50;4.42\<0.001Origin Immigrant1941140872,553327,5Ref Native3905213854,8176745,22,79(2,40;3,24)\<0,001Cohabitation status Group65143166,222033,8Ref Alone55427649,827850,21,21(0,91;1,60)0,174 Homeless100252575751,99(1,14;3,57)\<0.001 Confinement803847,54252,51,70(0,98;2,97)0,056 With Family4293268362,5161037,50,89(0,72;1,11)0,317 Unknown1689355,47544,61,35(0,89;2,04)0,147Alcohol No4475307968,8139631,2Ref Yes137146734,190465,92,85(2,46;3,31)\<0,001IDU No5768353261,2223638,8 Yes781417,96482,12.78(1.48;5.52)\<0,001HIV No4547278361,2176438,80,81(0,34;2,07)0,646 Yes26910840,116159,91,48(0,59;3,94)0,412 Unknown103065563,537536.4RefPrior Treatment No5287324561,4204238,6Ref Yes43822451,121448,91,12(0,89;2,04)0,314Localization Extra-pulmonary61149781,311418,7Ref Pulmonary4149229955,4185044,61,61(1,16;2,24)\<0,001 Disseminated30119865,810334,21,12(0,73;1,70)0,59 Unknown78555270,323329,71,14(0,80;1,63)0,458Radiology Normal61048078,713021,3Ref Abnormall cavitary192288946,3103353,71,99(1,43;2,79)\<0,001 Abnormal non cavitary3114204265,6107233,41,24(0,91;1,70)0,167 Unknown20013567,56532,51,21(0,77;1,89)0,4Microbiology Culture (−)105577973,827626,2Ref Microscopy smear (+)31441636521508481,39(1,14;1,71)\<0,001 Microscopy smear (+), culture (−)1647113168,751631,31,01(0,82;1,24)0,896*OR* odds ratio*CI* confidence interval*IDU* injecten drug users*HVI* humanimmunodeficiency virus

Discussion {#Sec5}
==========

We observed a high prevalence of smoking among individuals diagnosed with TB in Spain between 2006 and 2013. Smoking was associated with male gender, being native Spanish, the consumption of other drugs, a precarious social position, more severe and more developed lung disease, and poorer treatment outcome than in non-smoking TB patients.

In this study, we found that 39.3 % of TB patients were regular smokers at the time of diagnosis, a much higher figure than that reported for the general population in Spain, 23.95 %, according to data from the National Health Survey 2011--2013 and it remained well above this value, and with little annual variation (Fig. [1](#Fig1){ref-type="fig"}); this level was similar to that published for Catalonia in 2002 (34.9 %) \[[@CR12]\]. However, during the period of this study, we observed a steady decline in smoking prevalence in Spain, 26.44 % in 2006 to 23.95 % in 2013 \[[@CR21]\], as a result of legislative changes and prevention programs \[[@CR22]\]. Thus, the TB patients smokers may be resistant to general anti-smoking measures, possibly for social reasons or because of differences in its level of addiction to nicotine. This hinders smoking cessation in this group, and highlights the need for a different set of cessation strategies to those used in the general population.

In our sample, we found that men smoke significantly more than women; 62 % of men with TB were smokers, compared to 27.87 % of males in the general population during the same period. In comparison, the prevalence of smoking among female TB patients (25.3 %) was only 5 percentage points higher than in the general population (20.2 %). Worldwide, TB is known to be more common in men than in women. A study conducted in 22 countries with a high burden of TB found that smoking was a predictor of increased reporting of TB in males \[[@CR23]\], suggesting that the differences in disease rates between sexes could be due to the higher prevalence of smoking in men, a pattern that persists in virtually all ethnic groups and countries \[[@CR2]\].

While a third of the cases included in this study were foreigners, the prevalence of smoking was much lower in this group (27.5 %) than in native Spanish patients (45.2 %). Previous studies carried out in Spain show that the intensity of drug and alcohol consumption is lower in the immigrant population than in natives. This pattern has been attributed to cultural differences and economic difficulties that reduce consumption, and is maintained in immigrants with TB \[[@CR24]\].

Smoking was also associated with situations of social precariousness, and its prevalence was significantly higher among individuals who live alone, in poverty, or in confinement, regardless of their age or employment status. Smoking was also associated with pathological alcohol consumption (65.9 %) and injected drug use (82.1 %). These risk factors are classically associated with TB in people at risk of social marginalization, as previously described in our setting \[[@CR12], [@CR24], [@CR25]\]. The proportion of HIV co-infection was low in this sample (4.6 %), and HIV was associated with tobacco use in the bivariate but not multivariate analysis, possibly because of the low number of co-infected cases. The clinical presentation of TB in smokers was mainly pulmonary and disseminated, while isolated extra-pulmonary TB was rare in smokers. Radiologically, we also observed more extensive lesions in these patients, with more frequent cavitation and positive smear results at the time of diagnosis. These findings are similar to those reported by other authors, mentioned above, and reflect generally more serious and advanced disease \[[@CR12], [@CR13]\]. Several studies in animal models and humans have shown that exposure to tobacco smoke causes immunological changes, acting on alveolar macrophages by decreasing the production of TNF-α, IFN-γ, and mucociliary clearance, promoting disease progression \[[@CR26]--[@CR28]\], delaying sputum conversion and thereby extending the period of transmissibility \[[@CR29]\]. In this sense, and in contrast to other studies \[[@CR12]\], the observed delay in diagnosis was also higher in smokers, possibly because cough is a common symptom in these patients, and it may be difficult to perceive changes that alert the subject and motivate them to seek medical advice.

We did not find any significant differences between smokers and non-smokers in the presence of single or multi-drug resistance, or in the treatment initially indicated, although directly observed therapy was indicated more frequently in smokers than in non-smokers. Poorer treatment outcome was also more common among smokers. Therefore, smokers require closer monitoring and greater resources to ensure therapeutic compliance and the ultimate success of treatment, leading to increased healthcare spending. Other studies have also found a greater need for hospitalization, longer stays \[[@CR12]\], and increased risk of relapse following treatment. A study in Taiwan found that people who smoke more than 10 cigarettes per day have twice the risk of relapse of non-smokers after proper treatment \[[@CR14]\]. In our series, 7.5 % of patients had a history of previous illness, which was significantly with smoking.

Our study has some limitations. Our work can only show association between smoking and tuberculosis from an epidemiological point of view, and cannot show causality.

We did not quantify daily tobacco consumption, the number of years of smoking, type of tobacco used, or the intensity of passive smoking, which prevents us from evaluating a possible dose-response relationship. Only smoking status at the time of diagnosis was recorded, and we cannot determine if this persisted throughout the patient's follow-up. Thus, it was not possible to assess the impact of smoking cessation on disease progression or the treatment outcome.

We could not collect systematic information on smoking cessation interventions by health professionals, since this survey depended solely on routine clinical practice and the experience of the individual medical teams in each of the participating centers. Some centers gave brief anti-smoking counseling, along with basic health education during each visit. This type of intervention has previously proven useful and feasible in other TB treatment programs \[[@CR30]\], but is not included in local or national recommendations or regulations in our setting. The introduction of drug therapy for smoking cessation in patients with TB is still a pending task, given the limited clinical experience available \[[@CR31]\]; few professionals feel prepared to advise their TB patients on smoking cessation \[[@CR32]\], and cessation drugs are not widely accessible due to their high price because Spain are not subsidized by the National Health System and makes it impossible the access groups with economic difficulties as they are often patients with TB.

One of this study's strong points is the large number of cases recruited representing 12 % of total cases reported in the regions that are part of the Spanish state during the study period \[[@CR33]\] and the quality of the information, which allowed us to analyze trends in prevalence during the study period and to evaluate factors associated with smoking among TB patients.

Conclusion {#Sec6}
==========

The prevalence of smoking among TB patients in Spain is high. Smokers with TB have a distinct sociodemographic, clinical, radiological and microbiological profile to non-smokers. A detailed understanding of the prevalence of smoking in our setting, as well as sociodemographic, clinical and developmental factors associated with smoking among TB patients is the first step towards designing effective strategies for control and monitoring, with the aim of improving the care of these patients, their clinical progression, and the treatment outcome.
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